Swiss National Bank Sells 500 Shares of Masimo Corporation $MASI

Swiss National Bank decreased its position in shares of Masimo Corporation (NASDAQ:MASI) by 0.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,700 shares of the medical equipment provider’s stock after selling 500 shares during the period. Swiss National Bank owned 0.16% of Masimo worth $14,753,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Durable Capital Partners LP purchased a new stake in shares of Masimo during the 1st quarter valued at $187,528,000. Westfield Capital Management Co. LP grew its stake in Masimo by 75.9% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider’s stock worth $198,702,000 after buying an additional 509,724 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Masimo by 25.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,470,393 shares of the medical equipment provider’s stock valued at $415,570,000 after buying an additional 502,555 shares in the last quarter. Nuveen LLC purchased a new stake in Masimo in the first quarter valued at about $25,830,000. Finally, Alyeska Investment Group L.P. raised its stake in Masimo by 24.9% in the first quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock valued at $120,374,000 after buying an additional 143,899 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on MASI shares. Piper Sandler increased their price objective on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 6th. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Bank of America started coverage on shares of Masimo in a research note on Monday, November 17th. They set a “neutral” rating and a $162.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and set a $198.00 price objective on shares of Masimo in a report on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Masimo has a consensus rating of “Hold” and an average price target of $188.40.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $143.96 on Thursday. The company has a 50 day simple moving average of $145.71 and a two-hundred day simple moving average of $152.58. The stock has a market cap of $7.73 billion, a price-to-earnings ratio of -16.90 and a beta of 1.28. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. Masimo Corporation has a 12 month low of $133.70 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. The firm had revenue of $617.00 million for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. As a group, analysts predict that Masimo Corporation will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.